PURPOSE: Perilobar nephrogenic rests (PLNRs) are abnormally persistent foci of embryonal immature blastema that have been associated with dysregulation at the 11p15 locus by genetic/epigenetic means and are thought to be precursor lesions of Wilms tumor. The precise genomic events are, however, largely unknown. EXPERIMENTAL DESIGN: We used array comparative genomic hybridization to analyze a series of 50 PLNRs and 25 corresponding Wilms tumors characterized for 11p15 genetic/epigenetic alterations and insulin-like growth factor-II expression. RESULTS: The genomic profiles of PLNRs could be subdivided into three categories: those with no copy number changes (22 of 50, 44%); those with single, whole chromosome alterations (8 of 50, 16%); and those with multiple gains/losses (20 of 50, 40%). The most frequent aberrations included 1p- (7 of 50, 14%) +18 (6 of 50, 12%), +13 (5 of 50, 10%), and +12 (3 of 50, 6%). For the majority (19 of 25, 76%) of cases, the rest harbored a subset of the copy number changes in the associated Wilms tumor. We identified a temporal order of genomic changes, which occur during the insulin-like growth factor-II/PLNR pathway of Wilms tumorigenesis, with large-scale chromosomal alterations such as 1p-, +12, +13, and +18 regarded as "early" events. In some of the cases (24%), the PLNRs harbored large-scale copy number changes not observed in the concurrent Wilms tumor, including +10p, +14q, and +18. CONCLUSIONS: These data suggest that although the evidence for PLNRs as precursors is compelling, not all lesions must necessarily undergo malignant transformation.
PURPOSE: Perilobar nephrogenic rests (PLNRs) are abnormally persistent foci of embryonal immature blastema that have been associated with dysregulation at the 11p15 locus by genetic/epigenetic means and are thought to be precursor lesions of Wilms tumor. The precise genomic events are, however, largely unknown. EXPERIMENTAL DESIGN: We used array comparative genomic hybridization to analyze a series of 50 PLNRs and 25 corresponding Wilms tumors characterized for 11p15 genetic/epigenetic alterations and insulin-like growth factor-II expression. RESULTS: The genomic profiles of PLNRs could be subdivided into three categories: those with no copy number changes (22 of 50, 44%); those with single, whole chromosome alterations (8 of 50, 16%); and those with multiple gains/losses (20 of 50, 40%). The most frequent aberrations included 1p- (7 of 50, 14%) +18 (6 of 50, 12%), +13 (5 of 50, 10%), and +12 (3 of 50, 6%). For the majority (19 of 25, 76%) of cases, the rest harbored a subset of the copy number changes in the associated Wilms tumor. We identified a temporal order of genomic changes, which occur during the insulin-like growth factor-II/PLNR pathway of Wilms tumorigenesis, with large-scale chromosomal alterations such as 1p-, +12, +13, and +18 regarded as "early" events. In some of the cases (24%), the PLNRs harbored large-scale copy number changes not observed in the concurrent Wilms tumor, including +10p, +14q, and +18. CONCLUSIONS: These data suggest that although the evidence for PLNRs as precursors is compelling, not all lesions must necessarily undergo malignant transformation.
Authors: Richard Redon; Shumpei Ishikawa; Karen R Fitch; Lars Feuk; George H Perry; T Daniel Andrews; Heike Fiegler; Michael H Shapero; Andrew R Carson; Wenwei Chen; Eun Kyung Cho; Stephanie Dallaire; Jennifer L Freeman; Juan R González; Mònica Gratacòs; Jing Huang; Dimitrios Kalaitzopoulos; Daisuke Komura; Jeffrey R MacDonald; Christian R Marshall; Rui Mei; Lyndal Montgomery; Kunihiro Nishimura; Kohji Okamura; Fan Shen; Martin J Somerville; Joelle Tchinda; Armand Valsesia; Cara Woodwark; Fengtang Yang; Junjun Zhang; Tatiana Zerjal; Jane Zhang; Lluis Armengol; Donald F Conrad; Xavier Estivill; Chris Tyler-Smith; Nigel P Carter; Hiroyuki Aburatani; Charles Lee; Keith W Jones; Stephen W Scherer; Matthew E Hurles Journal: Nature Date: 2006-11-23 Impact factor: 49.962
Authors: Michael B Major; Nathan D Camp; Jason D Berndt; Xianhua Yi; Seth J Goldenberg; Charlotte Hubbert; Travis L Biechele; Anne-Claude Gingras; Ning Zheng; Michael J Maccoss; Stephane Angers; Randall T Moon Journal: Science Date: 2007-05-18 Impact factor: 47.728
Authors: R Natrajan; R D Williams; S N Hing; A Mackay; J S Reis-Filho; K Fenwick; M Iravani; H Valgeirsson; A Grigoriadis; C F Langford; O Dovey; S G Gregory; B L Weber; A Ashworth; P E Grundy; K Pritchard-Jones; C Jones Journal: J Pathol Date: 2006-09 Impact factor: 7.996
Authors: Rachael Natrajan; Jorge S Reis-Filho; Suzanne E Little; Boo Messahel; Marie-Anne Brundler; Jeffrey S Dome; Paul E Grundy; Gordan M Vujanic; Kathy Pritchard-Jones; Chris Jones Journal: Cancer Res Date: 2006-12-01 Impact factor: 12.701
Authors: Suzanne E Little; Raisa Vuononvirta; Jorge S Reis-Filho; Rachael Natrajan; Marjan Iravani; Kerry Fenwick; Alan Mackay; Alan Ashworth; Kathy Pritchard-Jones; Chris Jones Journal: Genomics Date: 2005-11-02 Impact factor: 5.736
Authors: Andrew J Murphy; Jason R Axt; Christian de Caestecker; Janene Pierce; Hernan Correa; Erin H Seeley; Richard M Caprioli; Mark W Newton; Mark P de Caestecker; Harold N Lovvorn Journal: Int J Cancer Date: 2012-04-04 Impact factor: 7.396
Authors: Linda Holmquist Mengelbier; Jenny Karlsson; David Lindgren; Ingrid Øra; Margareth Isaksson; Ildiko Frigyesi; Attila Frigyesi; Johannes Bras; Bengt Sandstedt; David Gisselsson Journal: Am J Pathol Date: 2010-09-16 Impact factor: 4.307
Authors: Raisa Vuononvirta; Neil J Sebire; Boo Messahel; Nina Perusinghe; Jorge S Reis-Filho; Kathy Pritchard-Jones; Gordan M Vujanic; Chris Jones Journal: Clin Cancer Res Date: 2009-03-24 Impact factor: 12.531
Authors: Dorine A Bax; Alan Mackay; Suzanne E Little; Diana Carvalho; Marta Viana-Pereira; Narinder Tamber; Anita E Grigoriadis; Alan Ashworth; Rui M Reis; David W Ellison; Safa Al-Sarraj; Darren Hargrave; Chris Jones Journal: Clin Cancer Res Date: 2010-06-22 Impact factor: 12.531
Authors: Mariana Maschietto; Jocelyn Charlton; Daniela Perotti; Paolo Radice; James I Geller; Kathy Pritchard-Jones; Mark Weeks Journal: Oncotarget Date: 2014-09-30
Authors: Katarzyna Taran; Tomasz Frączek; Anita Sikora-Szubert; Anna Sitkiewicz; Wojciech Młynarski; Józef Kobos; Piotr Paneth Journal: Oncotarget Date: 2016-11-22
Authors: Jocelyn Charlton; Richard D Williams; Neil J Sebire; Sergey Popov; Gordan Vujanic; Tasnim Chagtai; Marisa Alcaide-German; Tiffany Morris; Lee M Butcher; Paul Guilhamon; Stephan Beck; Kathy Pritchard-Jones Journal: Genome Med Date: 2015-02-02 Impact factor: 11.117